IDH1 peptide vaccine for glioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 May 2015: Trial registered, NCT02454634
  2. 19 Sep 2017: Trial completed, NCT02454634

The trials

NCT02454634: Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas

State
Completed
Phase
Phase 1
People
39 taking part
Started
Jun 2015
Primary completion
19 Sep 2017
Arms
IDH1 peptide vaccine
Results
None posted
  1. 27 May 2015: Trial registered
  2. 19 Sep 2017: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.